New regulations for national HIV drug resistance research released, Aidea Pharma deeply involved

On July 6th, Aidea Pharma announced that the National Medical Products Administration's Drug Evaluation Center has released the "Guidelines for Clinical Resistance Studies and Data Submission for Anti-HIV Infection Drugs," laying a solid regulatory foundation for the development of anti-HIV drugs. Notably, as early as September 2024, Aidea Pharma, as a leader in domestic anti-HIV drug development, was invited to participate in the expert consultation meeting for the draft of these guidelines and was deeply involved in the process